JPH0824583B2 - DNA extraction method - Google Patents
DNA extraction methodInfo
- Publication number
- JPH0824583B2 JPH0824583B2 JP11536989A JP11536989A JPH0824583B2 JP H0824583 B2 JPH0824583 B2 JP H0824583B2 JP 11536989 A JP11536989 A JP 11536989A JP 11536989 A JP11536989 A JP 11536989A JP H0824583 B2 JPH0824583 B2 JP H0824583B2
- Authority
- JP
- Japan
- Prior art keywords
- dna
- filter
- leukocytes
- white blood
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 34
- 238000007400 DNA extraction Methods 0.000 title claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 7
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 239000002657 fibrous material Substances 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 8
- 229920001917 Ficoll Polymers 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
【発明の詳細な説明】 〈産業上の利用分野〉 本発明はサザン・ハイブリダイゼーション(Southern
hybridization)などに用いる白血球DNAを抽出するた
めの効率的なDNAの抽出方法に関するものである。DETAILED DESCRIPTION OF THE INVENTION <Field of Industrial Application> The present invention relates to Southern hybridization (Southern
hybridization) and the like for an efficient DNA extraction method for extracting white blood cell DNA.
〈従来の技術〉 近年、遺伝子操作技術の目覚ましい発展により、種々
の疾患を遺伝子レベルで解析することが可能になりつつ
ある。たとえば末梢血管から採取された血液の白血球か
ら複雑な方法でゲノムDNAを抽出した後、サザン・ハイ
ブリダイゼーションなどの手法を用いて解析し、遺伝疾
患などの診断を行うなどである。<Conventional Technology> In recent years, with the remarkable development of gene manipulation technology, it is becoming possible to analyze various diseases at the gene level. For example, the genomic DNA is extracted from leukocytes of blood collected from peripheral blood vessels by a complicated method and then analyzed using a technique such as Southern hybridization to diagnose a genetic disease or the like.
サザン・ハイブリダイゼーション法は、細胞(白血
球、リンパ球)からDNAを抽出した後、制限酵素を用い
てDNAを切断し、の切断されたDNAを電気泳動した後メン
ブランフィルタに移し(ブロッティングという)、それ
からメンブランフィルタを軽く洗浄した後オーブンで乾
燥させ、好ましくはフィルタの非特異吸着を減少させる
操作を行った後32Pで標識した変性プローブDNAを加えて
ハイブリダイゼーションを行い、これを洗浄してオート
ラジオグラフィーでプロウイルスDNAや遺伝子の欠損、
変異等の多型を検出するものであり、従来、DNAは一般
にフィコル法(Ficoll)によって分離された白血球から
抽出されていた。In the Southern hybridization method, DNA is extracted from cells (white blood cells and lymphocytes), the DNA is cut with a restriction enzyme, the cut DNA is electrophoresed, and then transferred to a membrane filter (called blotting), Then, wash the membrane filter lightly and then dry it in an oven, preferably perform an operation to reduce nonspecific adsorption of the filter, and then add denatured probe DNA labeled with 32 P to perform hybridization. Radiographic defects in proviral DNA and genes,
It detects polymorphisms such as mutations, and conventionally, DNA has generally been extracted from leukocytes separated by the Ficoll method.
しかしながら、上記フィコル法は、「ヘパリンなどの
抗凝固剤を添加した血液に等量のリン酸緩衝食塩液(PB
S、PH7.4)を加えて良く混和し、これを分離剤を収容し
たスピッツ管に静かに注入して、稀釈した血液試料を分
離剤の上に重層し、400g30分遠心した後、白血球を含む
中間層を掻き乱さぬよう上層を取り除き、さらに上下層
を若干含む中間層を採取してこれを別のスピッツ管に採
りPBSを加えて混和し洗浄を行い、これを今度は160g10
分遠心し、さらに、上清を取り除きPBSを加えて混和し1
00g10分遠心するという操作を2回繰り返した後、上清
を取り除き必要とする溶媒に浮遊させ、最後に顕微鏡で
数を算定し、白血球の数を必要数に調整する。」という
ものであり、操作が非常に煩雑であり、また操作者の熟
練を要するものであった。However, the Ficoll method described above is similar to that of "equal amount of phosphate-buffered saline (PB
S, PH7.4) and mixed well, gently injecting this into the Spitz tube containing the separating agent, overlaying the diluted blood sample on the separating agent, centrifuging at 400 g for 30 minutes, and then removing white blood cells. The upper layer was removed so as not to disturb the intermediate layer containing it, and the intermediate layer containing a little upper and lower layers was collected, collected in another Spitz tube, mixed with PBS and washed, and this time 160 g 10
Centrifuge for minutes, remove the supernatant, add PBS and mix.
After repeating the operation of centrifuging at 00g for 10 minutes twice, the supernatant is removed and suspended in a required solvent, and finally the number is counted with a microscope to adjust the number of white blood cells to the required number. The operation is very complicated, and the skill of the operator is required.
〈発明の解決しようとする課題〉 本発明は如上の事情に鑑みてなされたもので、操作が
簡単で、熟練を要せず、かつ効率のよいDNAの抽出方法
を提供することを目的とする。<Problems to be Solved by the Invention> The present invention has been made in view of the above circumstances, and an object thereof is to provide a DNA extraction method that is easy to operate, does not require skill, and is efficient. .
〈課題を解決するための手段〉 本発明は上記の課題を解決するために、(ア)平均直
径10μm以下の繊維状物質が容器に充填されてなるフィ
ルタを用いて、血液から白血球を吸着分離する。(イ)
前記フイルタに吸着された白血球を洗浄液で洗浄して、
ヘモグロビン等の蛋白質を除去する。(ウ)該白血球を
マイナス20℃以下の低温でフィルタごと凍結し後、室温
で解凍する。の各工程を含んでなるDNAの抽出方法を採
用している。<Means for Solving the Problems> In order to solve the above problems, the present invention (a) adsorbs and separates leukocytes from blood using a filter having a container filled with a fibrous substance having an average diameter of 10 μm or less. To do. (I)
The white blood cells adsorbed on the filter are washed with a washing solution,
Remove proteins such as hemoglobin. (C) The white blood cells are frozen together with the filter at a low temperature of -20 ° C or lower, and then thawed at room temperature. The DNA extraction method including each step of is adopted.
〈作用〉 本発明によれば、フィルタに血液を通すと、血液中の
白血球は殆ど繊維状物質に吸着され、血液の他の成分と
分離される。このフィルタに洗浄液の例えばTE(10mMト
リス〔ヒドロキシメチル〕アミノエタン1mM EDTA、PH7.
6)を通して洗浄すると、ヘモグロビン等の蛋白質が除
去される。こうして分離洗浄された白血球をフィルタご
と例えば−80℃で凍結した後、室温で放置して白血球を
解凍する。それから繊維状物質にTE−mix(TE、10mM Na
cl、1.5mM Mgcl2、PH7.5)を加えると、フィルタの繊維
状物質に吸着されていた白血球は繊維状物質から容易に
回収される。<Operation> According to the present invention, when blood is passed through the filter, most leukocytes in the blood are adsorbed by the fibrous substance and separated from other components of the blood. For example, TE (10 mM tris [hydroxymethyl] aminoethane 1 mM EDTA, PH7.
Washing through 6) removes proteins such as hemoglobin. The white blood cells separated and washed in this manner are frozen together with the filter at, for example, −80 ° C., and then left at room temperature to thaw the white blood cells. Then, TE-mix (TE, 10 mM Na
cl, 1.5 mM Mgcl 2 , PH7.5), leukocytes adsorbed on the fibrous material of the filter are easily recovered from the fibrous material.
回収された白血球からゲノムDNAを抽出する操作は、
周知の方法で行うことが出来る。The operation of extracting genomic DNA from the collected white blood cells is
It can be performed by a known method.
〈実施例〉 次に本発明の実施例について説明する。<Example> Next, an example of the present invention will be described.
本発明のDNAの抽出方法は、(ア)平均直径10μm以
下の繊維状物質が容器に充填されてなるフィルタを用い
て、血液から白血球を吸着分離する。(イ)前記フィル
タに吸着された白血球を洗浄液で洗浄して、ヘモグロビ
ン等の蛋白質を除去する。(ウ)該白血球をマイナス20
℃以下の低温でフィルタごと凍結した後、室温で解凍す
る。の各工程を含んでなるものであり、白血球解凍後、
フィルタから繊維状物質を取り出し、これにたとえばTE
−mixなどの緩衝液を加えて白血球をたとえばスピッツ
管など適宜の試験管に回収し、更にこれにたとえば10%
硫酸ドデシルナトリウム(SDS)などの界面活性剤と蛋
白分解酵素(Protein ase K)を加えて、65℃で15時間
インキュベートし、これに熱処理したRNA分解酵素(RNa
seA)を加えて37℃で1時間インキュベートする。それ
からこれをフェノール試薬で処理し、DNAをエタノール
で沈澱させ精製するものである。蛋白分解酵素を加える
のは、DNAを含んでいる細胞の蛋白質やDNAをつなぎ合わ
せるための蛋白質(ヒストン等)を分解するためであ
り、またRNaseAを加えるのは、RNAとDNAの親和力の方が
DNAとDNAのそれより大なためにRNAがDNAに混じるとハイ
ブリダイゼーションを行った時にプローブDNAに対する
阻害作用を示すことがあるからである。In the DNA extraction method of the present invention, (a) leukocytes are adsorbed and separated from blood using a filter in which a container is filled with a fibrous substance having an average diameter of 10 μm or less. (A) The white blood cells adsorbed on the filter are washed with a washing solution to remove proteins such as hemoglobin. (C) minus 20 of the white blood cells
Freeze the whole filter at a low temperature below ℃ and thaw it at room temperature. After each step of thawing white blood cells,
Remove the fibrous material from the filter and put it into
-Add a buffer such as mix to collect leukocytes in an appropriate test tube such as a Spitz tube, and add 10% to this.
A surfactant such as sodium dodecyl sulfate (SDS) and a proteinase (Proteinase K) were added, and the mixture was incubated at 65 ° C for 15 hours, and then heat-treated, followed by RNAase (RNa
seA) and incubate at 37 ° C for 1 hour. Then, this is treated with a phenol reagent and the DNA is precipitated with ethanol for purification. The addition of proteolytic enzyme is for degrading the protein of cells containing DNA and the protein for binding DNA (Histone etc.), and the addition of RNaseA is due to the affinity of RNA and DNA.
This is because when the RNA is mixed with the DNA because it is larger than that of the DNA and the DNA, it may show an inhibitory effect on the probe DNA when the hybridization is performed.
繊維状物質としては、ポリエステルやポリアミド、
綿、ポリアクリルニトリルが使用可能であり、特にポリ
エステルが白血球回収率が高く好ましい。繊維状物質を
充填する容器は、血液を流入させ排出させることのでき
る開口を有するものであり、たとえば注射器や市販の白
血球除去フィルタのケースなどが挙げられる。フィルタ
に吸着された白血球を洗浄するための洗浄液は、繊維状
物質に付着したヘモグロビン等の蛋白質を除去するため
のもので、一般にTEが使用される。As the fibrous substance, polyester or polyamide,
Cotton and polyacrylonitrile can be used, and polyester is particularly preferable because of high leukocyte recovery rate. The container filled with the fibrous substance has an opening through which blood can flow in and out, and examples thereof include a syringe and a case of a commercially available leukocyte removal filter. The washing solution for washing the leukocytes adsorbed on the filter is for removing proteins such as hemoglobin attached to the fibrous substance, and TE is generally used.
白血球の凍結温度は、マイナス2℃以下であり、好ま
しくはマイナス20℃以下が良く、特にマイナス80℃前後
が良い。マイナス80℃前後で急速に冷凍した方が細胞を
傷めないで済むからである。尚、室温で放置して解凍す
るのはフィルタから白血球が剥がれやすくするためであ
り、解凍後の緩衝液は細胞に害を与えずPHを一定に保つ
ものが使用され、一般にTE−mixが使用される。TEの構
成要素としてEDTAが加えられているのは、2価の陽イオ
ンをEDTAで吸収することにより、2価の陽イオンと結合
し易いDNA分解酵素(DNAase)の反応を阻害するためで
ある。The freezing temperature of white blood cells is −2 ° C. or lower, preferably −20 ° C. or lower, particularly around −80 ° C. This is because cells are not damaged if they are frozen rapidly at around -80 ° C. It should be noted that the purpose of thawing at room temperature is to facilitate leukocyte detachment from the filter, and the buffer solution after thawing is used that keeps the pH constant without harming cells, and TE-mix is generally used. To be done. The reason that EDTA is added as a constituent element of TE is that it absorbs a divalent cation with EDTA and thereby inhibits the reaction of a DNA degrading enzyme (DNAase) that easily binds to the divalent cation. .
界面活性剤は白血球を溶解するためのものであり、こ
れを加えると白血球は速やかに溶解して内部のDNAなど
が出るため溶液は粘稠になる。界面活性剤は非イオン系
のもので生化学的に使用されるものであれば良く、SDS
の他にNP−40やトウイーン(Tween)等も使用可能であ
る。白血球の回収には緩衝液と界面活性剤をミックスし
たものを用いても良く、また細胞の溶解には界面活性剤
を蛋白分解酵素とミックスして用いても良い。The surfactant is for lysing leukocytes, and when this is added, leukocytes are rapidly lysed and internal DNA and the like are released to make the solution viscous. The surfactant should be non-ionic and biochemically used.
Besides, NP-40, Tween, etc. can be used. A mixture of a buffer solution and a surfactant may be used to recover leukocytes, and a surfactant may be mixed with a protease to lyse cells.
尚、解凍後の白血球の回収以降の操作については、た
とえば雑誌「臨床検査」(vol.32no.4 1988年4月)の
第393頁左欄、第4〜37行に紹介された方法など、適宜
の方法が選択可能である。For the operation after recovery of the white blood cells after thawing, for example, the method introduced in the left column of page 393, line 4 to 37 of the magazine “Clinical Examination” (vol.32 no.4 April 1988), etc. An appropriate method can be selected.
〔実施例1〕 試験管にヘパリン血(血液9.5mlにヘパリン0.5mlを加
えたもの)を10ml採り、これに生理食塩水10mlを加えた
ものを用意し、これを容量10mlの注射器に平均直径3.5
μmのポリエステル繊維80mg充填してなるフィルタに、
ペリスタポンプ(ダイアル目盛3)で引きながら流し込
み、白血球をポリエステル繊維に吸着させた。次に注射
器内の血液を排出して、ポリエステル繊維に付着してい
るヘモグロビン等の蛋白質をTE10ml(4〜10mlの任意量
で洗浄できる)で洗浄して除去した。次いで白血球を注
射器ごと−80℃で凍結したのち、これを室温で放置して
解凍した。それからポリエステル繊維を注射器から取り
出し、これにTE−mix4mlを加えて白血球を洗い出し回収
した。次いで回収された白血球に10%SDS200μl、蛋白
分解酵素50μl(5mg/ml)を加え65℃で15時間インキュ
ベートした。そしてさらにこれに熱処理したRNA分解酵
素3ml(10mg/ml)を加え、37℃で1時間インキュベート
し、これをフェノール試薬で処理し、エタノールで白血
球を沈澱させDNAを精製した。[Example 1] 10 ml of heparin blood (blood 9.5 ml plus heparin 0.5 ml) was taken in a test tube, and physiological saline 10 ml was added to the test tube. 3.5
In a filter filled with 80 mg of polyester fiber of μm,
It was poured while pulling with a peristaltic pump (dial scale 3) to adsorb leukocytes on the polyester fiber. Next, the blood in the syringe was discharged, and proteins such as hemoglobin attached to the polyester fiber were washed and removed with 10 ml of TE (which can be washed with any amount of 4 to 10 ml). Then, the white blood cells were frozen together with the syringe at −80 ° C. and then left at room temperature for thawing. Then, the polyester fiber was taken out from the syringe, and 4 ml of TE-mix was added thereto to wash and collect leukocytes. Next, 200 μl of 10% SDS and 50 μl of proteolytic enzyme (5 mg / ml) were added to the collected leukocytes and incubated at 65 ° C. for 15 hours. Then, 3 ml (10 mg / ml) of heat-treated RNA degrading enzyme was added thereto, and the mixture was incubated at 37 ° C. for 1 hour, treated with a phenol reagent, and leukocytes were precipitated with ethanol to purify DNA.
第1表は血液をフィルタに通す前と通した後の血液中
の白血球の量を測定した結果を示す。約93%の白血球が
吸着分離されたことが分かる。Table 1 shows the results of measuring the amount of white blood cells in the blood before and after passing the blood through the filter. It can be seen that about 93% of white blood cells were adsorbed and separated.
また図1はエタノール沈澱後、蒸留水にDNAを溶解さ
せ吸光度を測定した結果を示す。フィコール・ハイパー
ク(ファルマシア社製)を用いてDNAを回収(Ficoll
法)した時とほぼ同様のパターンを示しており、DNAが
回収されていることが分かる。吸光係数は10D=50mg/ml
であり、DNAは波長260nmのところに現れるから、本法を
用いた場合のDNAの回収量は33.5mg/mlであり、Ficoll法
を用いた場合(5.6mg/mlよりも多い。Further, FIG. 1 shows the results of measuring the absorbance by dissolving DNA in distilled water after ethanol precipitation. DNA recovery using Ficoll Hyperc (Pharmacia)
The pattern is almost the same as that obtained when the method was performed), indicating that the DNA has been recovered. Extinction coefficient is 10D = 50mg / ml
Since the DNA appears at a wavelength of 260 nm, the amount of DNA recovered using this method is 33.5 mg / ml, which is higher than that using the Ficoll method (more than 5.6 mg / ml).
〔実施例2〕 本法およびFicol法により回収されたDNAを制限酵素Bg
lIで消化し、電気泳動を行ったところ、第2図のような
パターンが得られた。 [Example 2] DNA recovered by this method and Ficol method was treated with restriction enzyme Bg.
When digested with 11 and electrophoresed, a pattern as shown in FIG. 2 was obtained.
それぞれのパターンから今回発明した方法がゲノミッ
クサザーンの材料として使用できるものであることが推
定される。From each pattern, it is estimated that the method invented this time can be used as a material for genomic Southern.
尚、本法で用いたフィルタは実施例1におけるものと
同様のものである。The filter used in this method is the same as that used in the first embodiment.
〔実施例3〕 本法により回収された白血球がサザン・ハイブリダイ
ゼーションに使用可能であることを確認するために、本
法およびFicol法を用いて抽出したDNAを制限酵素BglIで
消化し、甲状腺刺激ホルモンのβ鎖をコードする遺伝子
をプローブ(約500bp)としてハイブリダイゼーション
を試みた。その結果得られたオートラジオグラムを第3
図に示す。[Example 3] In order to confirm that leukocytes recovered by this method can be used for Southern hybridization, DNA extracted by this method and Ficol method was digested with restriction enzyme BglI to stimulate thyroid gland. Hybridization was attempted using a gene encoding the β chain of the hormone as a probe (about 500 bp). The resulting autoradiogram is the third
Shown in the figure.
本法、Ficol法ともに、4.4kb付近に一本のバンドが見
られた。このことから、本法を用いて抽出したDNAもFic
ol法を用いて抽出したDNAと同様に、実際の分析に使用
可能であることが分かる。In both this method and Ficol method, one band was observed at around 4.4 kb. From this, the DNA extracted using this method is also Fic.
It can be seen that it can be used for actual analysis as well as the DNA extracted using the ol method.
尚、本法で用いたフィルタは実施例1におけるものと
同じものである。The filter used in this method is the same as that used in the first embodiment.
〈発明の効果〉 本発明によれば、次のような効果を奏することが出来
る。<Effects of the Invention> According to the present invention, the following effects can be achieved.
(1)白血球を繊維状物質に吸着分離してこれを洗浄し
回収するものなので、操作が簡単であり、また白血球の
純度も高い。(1) Since leukocytes are adsorbed and separated on fibrous substances and washed and collected, the operation is simple and the purity of leukocytes is high.
(2)白血球を凍結後これを室温で解凍しているので、
繊維状物質の吸着能が殆ど無くなっており、吸着された
白血球の略全量を容易にかつ効率的に回収することがで
のる。(2) Since white blood cells are frozen and thawed at room temperature,
Since the fibrous substance has almost no ability to be adsorbed, almost all the amount of adsorbed leukocytes can be easily and efficiently recovered.
(3)純度の高い白血球を容易にしかも効率良く回収す
ることができるので、DNAの抽出も容易かつ効率的に行
うことができる。(3) Since highly pure white blood cells can be easily and efficiently recovered, DNA can be extracted easily and efficiently.
第1図は本発明の方法はFicoll法により回収されたDNA
の吸光度を示すグラフであり、図中−○−は本法を用い
た場合、−△−はFicoll法を用いた場合である。また、
第2図はBglIによって消化されたDNAのパターンを示す
電気泳動図、第3図は第2図で用いたものと同じDNAに
ついて32P・TSHβプローブでハイブリダイゼーションを
行ったときのオートラジオグラムを示す図である。FIG. 1 shows that the DNA of the present invention was recovered by the Ficoll method.
FIG. 4 is a graph showing the absorbance of, wherein − ◯ − is the case where the present method is used, and −Δ− is the case where the Ficoll method is used. Also,
Fig. 2 is an electropherogram showing the pattern of DNA digested with BglI, and Fig. 3 is an autoradiogram of the same DNA used in Fig. 2 when hybridized with 32 P TSHβ probe. FIG.
Claims (3)
容器に充填されてなるフィルタを用いて、血液から白血
球を吸着分離する。 (イ)前記フイルタに吸着された白血球を洗浄液で洗浄
して、ヘモグロビン等の蛋白質を除去する。 (ウ)該白血球をマイナス20℃以下の低温でフィルタご
と凍結した後、室温で解凍する。の各工程を含んでなる
DNAの抽出方法。1. A) Leukocytes are adsorbed and separated from blood by using a filter having a container filled with a fibrous substance having an average diameter of 10 μm or less. (A) Leukocytes adsorbed on the filter are washed with a washing solution to remove proteins such as hemoglobin. (C) The white blood cells are frozen together with the filter at a low temperature of -20 ° C or lower, and then thawed at room temperature. Each step of
DNA extraction method.
綿、またはポリアクリロニトリルからなる請求項1記載
のDNAの抽出方法。2. The fibrous material is polyester, polyamide,
The method for extracting DNA according to claim 1, which comprises cotton or polyacrylonitrile.
出方法。3. The method for extracting DNA according to claim 2, wherein the washing solution is TE.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11536989A JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11536989A JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02295485A JPH02295485A (en) | 1990-12-06 |
JPH0824583B2 true JPH0824583B2 (en) | 1996-03-13 |
Family
ID=14660824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11536989A Expired - Fee Related JPH0824583B2 (en) | 1989-05-09 | 1989-05-09 | DNA extraction method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0824583B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6383783B1 (en) | 1999-09-21 | 2002-05-07 | 3M Innovative Properties Company | Nucleic acid isolation by adhering to hydrophobic solid phase and removing with nonionic surfactant |
KR100718220B1 (en) * | 2001-07-09 | 2007-05-15 | 아사히 가세이 가부시키가이샤 | Nucleic Acid Purification and Detection Using Nonwoven Fabrics |
EP1504121A4 (en) * | 2002-04-24 | 2005-06-29 | Hitachi Chemical Res Ct Inc | Device and method for high-throughput quantification of mrna from whole blood |
-
1989
- 1989-05-09 JP JP11536989A patent/JPH0824583B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH02295485A (en) | 1990-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Allfrey et al. | Methods for the purification of thymus nuclei and their application to studies of nuclear protein synthesis | |
Sharma et al. | “The FSGS Factor”: Enrichment and: in Vivo: Effect of Activity from Focal Segmental Glomerulosclerosis Plasma | |
JP4304348B2 (en) | DNA isolation method | |
EP0587951B1 (en) | Cell nuclei capture method and device used therefor | |
JP5755326B2 (en) | How to determine the characteristics of renal function | |
JP2001526182A (en) | Methods for nucleic acid isolation | |
Peten et al. | The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of alpha 2IV collagen mRNA expression by competitive polymerase chain reaction. | |
Connell et al. | The purification of haptoglobin | |
Vigushin et al. | Familial nephropathic systemic amyloidosis caused by apolipoprotein Al variant Arg26 | |
JP2002507121A (en) | RNA isolation method | |
JP2011200236A (en) | Process and reagent for extraction of rna from fractionated blood leukocyte | |
CN105506106A (en) | Method and primer for detecting whole exons of FIX gene | |
CN107904229A (en) | Genome DNA extracting method and extracts kit | |
Coates et al. | Genetic variation in human erythrocyte acetylcholinesterase | |
JP3018802B2 (en) | DNA extraction method and extraction kit from whole blood sample | |
Perez-Sanchez et al. | Use of cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: report of two cases | |
US7737268B2 (en) | Method of recovering nucleic acids and kit for recovering nucleic acids | |
Elmgreen et al. | Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. | |
CA1299104C (en) | Blood cell separation | |
Huisman et al. | Hemoglobin Grady: the first example of a variant with elongated chains due to an insertion of residues | |
Schlemper et al. | Familial essential thrombocythemia: clinical characteristics of 11 cases in one family | |
JPH0824583B2 (en) | DNA extraction method | |
JP6704563B2 (en) | Chaotrope and method for extracting genomic DNA using the chaotrope | |
Bertani et al. | Focal segmental membranous glomerulonephropathy associated with other glomerular diseases | |
Weng et al. | Hepatocyte nuclear factor-1β (MODY5) gene mutations in Scandinavian families with early-onset diabetes or kidney disease or both. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |